GDC-0994 (hydrochloride)

GDC-0994 (hydrochloride) Suppliers list
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Company Name: Dezhou LonWel Pharmaceutical Technology Co., Ltd.  
Tel: 13761310616
Email: 39324283@qq.com
Company Name: Musechem  
Tel: +1-800-259-7612
Email: info@musechem.com
GDC-0994 (hydrochloride) Basic information
Product Name:GDC-0994 (hydrochloride)
Synonyms:GDC-0994 (hydrochloride);GDC-0994 HCl;CS-2072;Ravoxertinib hydrochloride;RAVOXERTINIB HYDROCHLORIDE (GDC-0994 HYDROCHLORIDE);Ravoxertinib hydrochloride (GDC-0994
CAS:2070009-58-2
MF:C21H19Cl2FN6O2
MW:477.32
EINECS:
Product Categories:
Mol File:2070009-58-2.mol
GDC-0994 (hydrochloride) Structure
GDC-0994 (hydrochloride) Chemical Properties
storage temp. Store at -20°C
solubility DMSO: 100 mg/mL (209.50 mM)
form Solid
color Light yellow to yellow
Safety Information
HS Code 2924297099
MSDS Information
GDC-0994 (hydrochloride) Usage And Synthesis
UsesRavoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for ERK kinase activity with IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
in vivo

In CD-1 mice, a 10 mg/kg oral dose of Ravoxertinib is sufficient to achieve the desired target coverage for at least 8 h[1]. Daily, oral dosing of Ravoxertinib results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice[2].

IC 50ERK2: 3.1 nM (IC50); ERK1: 6.1 nM (IC50); p-RSK: 12 nM (IC50)
References[1] Blake JF, et al. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Developme DOI:10.1021/acs.jmedchem.6b00389
[2] Kirk Robarge, et al. Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014.
[3] MICHAEL LAI. Opportunity for Pharmaceutical Intervention in Lung Cancer: Selective Inhibition of JAK1/2 to Eliminate EMT-Derived Mesenchymal Cells.
GDC-0994 (hydrochloride) Preparation Products And Raw materials
Tag:GDC-0994 (hydrochloride)(2070009-58-2) Related Product Information
Sitagliptin Pyridoxal phosphate VRT752271 GlyT2-IN-1 tert-Butylhydroquinone Anti-Aging Compound Library